The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects

European Journal of Clinical Pharmacology

Volumn 35, Issue 1, 1988, Pages 53-57

  Dominiak, P ^a   Grevel, J ^b   Abisch, E ^c   Grobecker, H ^d   Dennler, H J ^e   Welzel, D ^e  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c Sandoz Pharma Ltd   (Switzerland)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e Sandoz Pharma Ltd   (Germany)

Author keywords

codergocrine; hydergine; pharmacokinetics; prolactin; systemic availability

Indexed keywords

DIHYDROERGOTOXINE; DIHYDROERGOTOXINE MESILATE;

BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; DIHYDROERGOTOXINE; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HUMAN; MALE; REFERENCE VALUES;

EID: 0023803139     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/BF00555507     Document Type: Article

References (20)

1. Drugs against brain hypoxia
2. Die Wirkung von CoDergocrinmesylat bei älteren Hypertonikern
3. Dihydroergotoxine kinetics in healthy men after intravenous and oral administration
4. Spezifität und Präzision einer radioimmunologischen Bestimmung von Dihydroergotoxin im Plasma
5. Hydergine pharmacokinetics in the elderly
6. Description of the time course of the prolactin suppressant effect of the dopamine agonist CQ201-403 by an integrated pharmacokinetic-pharmacodynamic model
7. Comparison of the bioavailability of Redergin tablets (1.0 mg) and Redergin solution
8. Untersuchungen zur Bioverfügbarkeit von Hydergin special
9. Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients
10. Comparative pharmacokinetic investigations with tritium-labelled ergot alkaloids after oral and intravenous administration in man
11. The ergoloid mesylate dihyroergotoxine: radioimmunoassay measurements on plasma and blood pressure-lowering activity
12. Effect of dihydroergokryptine administration on serum prolactin and growth hormone in normal, hyperprolactinaemic and acromegalic subjects: Evidence of potent and long-lasting pituitary dopamine receptor stimulation
13. Mechanisms of dihydroergotoxine's effect on prolactin release
14. Cardiovascular regulation during administration of co-dergocrine to normal subjects
15. Dihydroergotoxine decreases blood pressure in spontaneously hypertensive rats by interacting with peripheral dopamine receptors
16. Intramuscular ergotamine: Plasma levels and dynamic activity
17. Ein kinetisches Modell für einen endokrinen Effekt: Die prolaktinsenkende Wirkung von Mesulergin
18. Structure elucidation and receptor binding studies of the primary and major metabolite of dihydroergotamine in man
19. Investigation on the venoconstrictor effects of 8'hydroxy-dihydroergotamine, the main metabolite of dihydroergotamine, in man